Cheng Peng1, Yanshuo Ye1, Zhanpeng Wang1, Lianyue Guan1, Suriguga Bao2, Bo Li3, Wei Li4. 1. Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. 2. Department of Hepatobiliary-Pancreatic Surgery, Inner Mongolia people's Hospital, Hohhot, China. 3. Department of Epidemiology, School of Public Health of Jilin University, Changchun, China. 4. Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. Electronic address: weili888@hotmail.com.
Abstract
AIM: There are no existing biomarkers that demonstrate very reliable performance in the diagnosis of hepatocellular carcinoma (HCC), especially in the early stage. Studies have shown that numerous aberrantly expressed circulating microRNAs (miRNAs) can be used as a diagnostic tool for HCC; however, these studies have produced inconsistent results. METHODS: We performed a meta-analysis to summarize the diagnostic accuracy of circulating miRNAs, alpha-fetoprotein (AFP), and AFP combined with miRNAs in differentiating HCC patients from non-HCC controls, healthy controls and chronic liver disease controls. We also evaluated the diagnostic accuracy of circulating miRNAs for early-stage HCC. Furthermore, we systematically reviewed the diagnostic effectiveness of single miRNAs and individual miRNA panels. RESULTS: Circulating miRNAs showed good diagnostic performance. Compared with single miRNAs, the diagnostic accuracy of miRNA panels was clearly better. The combination of AFP and miRNAs improved the diagnostic accuracy compared with the use of miRNAs or AFP alone. For early-stage HCC patients, circulating miRNAs exhibited relatively satisfactory diagnostic accuracy. CONCLUSIONS: Circulating miRNAs can be used as an early diagnostic marker of HCC. The combination of miRNAs and AFP has great potential as a novel strategy for the diagnosis of HCC.
AIM: There are no existing biomarkers that demonstrate very reliable performance in the diagnosis of hepatocellular carcinoma (HCC), especially in the early stage. Studies have shown that numerous aberrantly expressed circulating microRNAs (miRNAs) can be used as a diagnostic tool for HCC; however, these studies have produced inconsistent results. METHODS: We performed a meta-analysis to summarize the diagnostic accuracy of circulating miRNAs, alpha-fetoprotein (AFP), and AFP combined with miRNAs in differentiating HCC patients from non-HCC controls, healthy controls and chronic liver disease controls. We also evaluated the diagnostic accuracy of circulating miRNAs for early-stage HCC. Furthermore, we systematically reviewed the diagnostic effectiveness of single miRNAs and individual miRNA panels. RESULTS: Circulating miRNAs showed good diagnostic performance. Compared with single miRNAs, the diagnostic accuracy of miRNA panels was clearly better. The combination of AFP and miRNAs improved the diagnostic accuracy compared with the use of miRNAs or AFP alone. For early-stage HCC patients, circulating miRNAs exhibited relatively satisfactory diagnostic accuracy. CONCLUSIONS: Circulating miRNAs can be used as an early diagnostic marker of HCC. The combination of miRNAs and AFP has great potential as a novel strategy for the diagnosis of HCC.
Authors: Heba M I Abdallah; Sally A El Awdan; Rehab F Abdel-Rahman; Abdel Razik H Farrag; Rasha M Allam Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: Gábor Lendvai; Tímea Szekerczés; Endre Kontsek; Arun Selvam; Attila Szakos; Zsuzsa Schaff; Mikael Björnstedt; András Kiss Journal: Pathol Oncol Res Date: 2020-07-12 Impact factor: 3.201
Authors: Robin Mjelle; Simona O Dima; Nicolae Bacalbasa; Konika Chawla; Andrei Sorop; Dana Cucu; Vlad Herlea; Pål Sætrom; Irinel Popescu Journal: BMC Cancer Date: 2019-10-28 Impact factor: 4.430